Eczema (Atopic Dermatitis)
main-banner
Eczema (Atopic Dermatitis)
INCB 18424-315 Enrolling

Clinical Trial for Adolescents with Eczema (60 Weeks)


Treatment: Topical Age: 12 Years

Adolescents aged 12 to under 18 years with a diagnosis of atopic dermatitis (AD) with duration of AD for at least 2 years, may qualify for this study.  Individuals must have mild to moderate AD (eczema), involving 3-20% of the body surface area (excluding the scalp).  In addition, eligible participants must have AD not adequately controlled with other topical prescription therapies or when those therapies are not advisable.

Participants will receive investigational topical treatment (active study drug) via a cream.  Study treatment and study-related assessments will be provided at no cost.  Compensation for study-related activities and reimbursement for time and travel may be provided.

Study participation will last approximately 60 weeks and involve about 12 visits to the study centre.


The following information is from ClinicalTrials.gov

Last Update Posted: January 29, 2023

Official Title

A Phase 3, Open-Label, One-Year Safety Study of Ruxolitinib Cream in Adolescents (Ages ≥ 12 Years to < 18 Years) With Atopic Dermatitis

ClinicalTrials.gov ID

NCT05456529

Sponsor

Incyte Corporation

Study Description

  • Brief Summary:

    The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).

  • Condition or Disease:

    Atopic Dermatitis (AD)

  • Intervention/Treatment:

    Drug: Ruxolitinib Cream
  • Phase:

    Phase 3

  • Ages Eligible for Study:

    12 Years and 17 Years (Child)

  • Sexes Eligible for Study:

    All

Inclusion Criteria:

A diagnosis of Atopic Dermatitis (AD) as defined by the Hanifin and Rajka (1980) criteria.
Duration of AD of at least 2 years.
Total IGA score of 2 to 3 at the screening and baseline visits.
Percent BSA (excluding the scalp) with AD involvement of 3% to 20% at the screening and baseline visits.
Atopic dermatitis not adequately controlled with other topical prescription therapies or when those therapies are not advisable.
Agree to discontinue all agents used to treat AD from screening through the final follow up visit.
Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

An unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to baseline.
Concurrent conditions and history of other diseases
Any current and/or history of serious illness or medical, physical, or psychiatric condition(s) that, in the investigator’s opinion, would interfere with full participation in the study, including application of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data. For example:
Clinically significant or uncontrolled cardiovascular disease, including unstable angina, acute myocardial infarction or stroke within 6 months from Day 1 of study cream application, New York Heart Association Class III or IV congestive heart failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood pressure > 150/90 mm Hg) unless approved by the medical monitor/sponsor.
Current and/or history of malignancy in the 5 years preceding the baseline visit, except for adequately treated, nonmetastatic nonmelanoma skin cancer.
Current and/or history of arterial or venous thrombosis, including DVT and PE.
Current and/or history of active tuberculosis or current and/or history of latent tuberculosis unless adequately treated.

Any of the following clinical laboratory test results at screening:

Hemoglobin < 100 g/L (< 10 g/dL) Liver function tests: AST or ALT ≥ 2.5 × ULN Total bilirubin > 1.5 × ULN with the exception of Gilbert disease. c. Estimated glomerular filtration rate < 30 mL/min/1.73 m2 (using the CKD Epidemiology Collaboration equation). d. Positive serology test results for HIV antibody. e. Any other clinically significant laboratory result that, in the opinion of the investigator, poses a significant risk to the participant. Use of any of the following treatments within the indicated washout period before baseline: 5 half-lives or 12 weeks, whichever is longer - biologic agents (eg, dupilumab). 4 weeks - systemic corticosteroids or adrenocorticotropic hormone analogues, cyclosporine, methotrexate, azathioprine, or other systemic immunosuppressive or immunomodulating agents (eg, mycophenolate or tacrolimus). 2 weeks - immunizations with live-attenuated vaccines; sedating antihistamines, unless on long-term stable regimen (nonsedating antihistamines are permitted). Note: Live-attenuated vaccines are not recommended during the CT period. Note: COVID-19 vaccination is allowed. 1 week - use of other topical treatments for AD (other than bland emollients, eg, Aveeno® creams, ointments, sprays, soap substitutes), such as topical antipruritics (eg, doxepin cream), corticosteroids, calcineurin inhibitors, PDE4 inhibitors, coal tar (shampoo), antibiotics, or antibacterial cleansing body wash/soap. Note: Diluted sodium hypochlorite "bleach" baths are allowed as long as they do not exceed 2 baths per week and their frequency remains the same throughout the study. Previously received systemic or topical JAK inhibitors (eg, ruxolitinib, tofacitinib, baricitinib, filgotinib, lestaurtinib, pacritinib). Ultraviolet light therapy or prolonged exposure to natural or artificial sources of UV radiation (eg, sunlight or tanning booth) within 2 weeks prior to the baseline visit and/or intention to have such exposure during the study, which is thought by the investigator to potentially impact the participant's AD. Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before baseline with another investigational medication or current enrollment in another investigational drug protocol. Current treatment or treatment within 30 days or 5 half-lives (whichever is longer) before baseline with a strong CYP3A4 inhibitor. Inability to draw blood for PK analysis from any nonlesional areas. Known allergy or reaction to any component of the study cream formulation. In the opinion of the investigator unable or unlikely to comply with the administration schedule and study evaluations. Further exclusion criteria may apply.


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.


Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

Dr. Darryl P. Toth

Dermatologist

Dr. Kim Alexander Papp

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found
about-icon

Learn More About

Eczema (Atopic Dermatitis)

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials